U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07124000) titled 'DESTINY-PANTUMOUR04' on Aug. 13.
Brief Summary: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Study Start Date: Aug. 31
Study Type: OBSERVATIONAL
Condition:
Adenocarcinoma (NOS)
Anal Cancer
Bladder Cancer
Cervical Cancer
Endometrial Cancer
Esophageal Cancer
Gall Bladder Cancer
Gastrointestinal Stromal Tumour
Head and Neck Cancer
Liver Cancer
Melanoma
Mouth Cance...